How much jwh 018 to get high

Alternatively, it might be predicted that production of less active metabolites by certain individuals would result in antagonistic effects with concurrently administered cannabinoids, potentially leading to greater use of synthetic cannabinoids in an attempt to overcome the reduction in effects.

Such complex effects could have unique and potentially harmful consequences on the delicate balance of the endocannabinoid system, which plays important roles in modulating mood [36] , appetite and energy homeostasis [37] , [38] , pain sensation [39] , immune function [40] , fertility [41] and possibly bone homeostasis [42]. Although several explanations are possible, cannabinoid receptor-independent GPCR activation in response to K2 use is probable. The possibility of CB1R-independence, both GPCR and non-GPCR mediated, is supported by the clinical observations of seizures, hallucinations, anxiety, agitation, panic attacks, and hypertension, which are not typically observed following CB1R activation.

The mechanisms behind these atypical adverse effects, although not completely understood themselves, nevertheless give additional information as to how K2 is acting in vivo. For example, grand mal seizures, which can occur with K2 use, are the result of excessive, aberrant neural synaptic firing that leads to involuntary tonic-clonic spasms.

The mechanisms behind grand mal seizures are complex and diverse, but ultimately involve disinhibition of excitatory neurons [43]. Retrograde activation of CB1Rs by cannabinoids and endocannabinoids hyperpolarizes presynaptic neurons and thus inhibits synaptic transmission [44] , and several cannabinoids have even been shown to exhibit anticonvulsive activity [45] , [46] , [47] , [48].

Theories underlying the neurobiological mechanisms of hallucinations and psychosis include abnormal dopaminergeric neurotransmission, as described in the dopamine hypothesis of schizophrenia [52] , serotonergic transmission, as seen with the serotonergic classical hallucinogens [53] , and NMDA glutamate receptor blockade [54].

Alteration of the receptor networks mentioned here are just a few examples of many possible that may result in severe adverse effects seen in an alarmingly large proportion of K2 users.

The present study investigates some previously unknown actions of oxidized products of JWH produced by using the relatively new and increasingly common drug of abuse, K2. Although JWH is a predominant component of K2, it is unfortunately only one of a whole host of cannabimimetic compounds found in varying, unregulated concentrations from brand-to-brand and, even within brands, batch-to-batch of K2.

This reality presents a challenge to researchers and clinicians in their attempts to better understand and predict the biological consequences of K2 use and thus accurately warn the general public about its risks, as well as advise legislators, who are currently working to determine the appropriate legal status of K2.

The uncontrolled and heterogeneous nature of K2 also presents a danger to even its more experienced users who may unknowingly use K2 containing particular synthetic cannabinoid blends to which they may have an adverse reaction.

Nonetheless, this work represents an important initial step toward understanding K2 by uncovering significant CB1R affinities and intrinsic activities of five potential metabolites of JWH Since JWH produces metabolites with partial to full agonist activity at CB1Rs, it is justified to posit that similar K2 synthetic cannabinoids can also be biotransformed into molecules with various levels of affinity and activity at CB1Rs, as well as at other receptor systems as discussed above.

Altogether, the presence of parent synthetic cannabinoid molecules within a single dose of K2, combined with the respective active metabolites produced, could conceivably act in concert to produce the dynamic range of effects observed following use of various K2 preparations. The idea that active metabolites are generated from not just one, but several parent molecules found within a single drug of abuse, is novel and exciting, but complicates matters by introducing an intrinsic polypharmacy effect.

In conclusion, the discovery that JWH metabolites, and other oxidized products of JWH, partake actively and diversely in the activity of K2 provides a substantial avenue of exploration and thus serves as an essential building block in combating problems associated with an increasingly common drug of abuse. Louis, MO , respectively. Louis, MO. To prepare crude membrane homogenates, brains were thawed on ice, pooled and suspended in ice-cold homogenization buffer 50 mM HEPES pH 7.

Supernatants were discarded and pellets were resuspended in ice cold homogenization buffer, homogenized and centrifuged similarly twice more. Assays were performed in triplicate, in a final volume of 1 mL, as previously described [59]. Total binding was defined as the amount of radioactivity observed when 0. Specific binding was calculated by subtracting non-specific from total binding. After overnight extraction, bound radioactivity was determined by liquid scintillation spectrophotometry.

Specific binding is expressed as a percentage of binding occurring in vehicle samples e. Louis, MO and water ad libitum until immediately before testing. Animals were acclimated to the laboratory environment 2 days prior to experiments and were tested in groups of 6 mice per condition. All studies were carried out in accordance with the Declaration of Helsinki and with the Guide for Care and Use of Laboratory animals as adopted and promulgated by the National Institutes of Health.

A rostral-caudal cut approximately 1. At least 7 days were imposed between surgery and experimental observation of drug effects to allow incisions to heal and mice to recover normal body weights. Following surgery, implanted mice were individually housed in Plexiglas mouse cages Implanted transmitters produced activity- and temperature-modulated signals that were transmitted to a receiver model ER Receiver, Mini Mitter Co.

Albans, VT equipped with exhaust fans, which further masked ambient laboratory noise. On experimental days, mice were weighed, marked, and returned to their individual cages during which at least 1 hr of baseline data were collected. Cannabinoid doses were then calculated and drugs prepared for injection.

Mice were then placed into a new cage with fresh bedding to stimulate exploratory behavior. Temperature and locomotor activity data were collected at regular 5-min intervals and processed simultaneously by the Vital View data acquisition system Mini Mitter Co.

Curve fitting and statistical analyses for in vitro experiments were performed using GraphPad Prism version 4. The Cheng-Prusoff equation [61] was used to convert the experimental IC 50 values obtained from competition receptor binding experiments to K i values, a quantitative measure of receptor affinity.

Non-linear regression for one-site competition was used to determine the IC 50 for competition receptor binding. For core body temperature experiments, the area under the curve AUC was calculated using a trapezoidal rule from 0—10 hr. For locomotor activity, total locomotor counts were summed from 0—10 hr. The authors would like to thank Ms. Browse Subject Areas? Given the emerging evidence for interactions between cannabinoid and 5-HT systems in the brain, we sought to determine the effects of repeated treatment with JWH on the behavioral responsiveness to selective 5-HT receptor agonists.

Body temperatures and catalepsy scores were determined during the repeated dosing regimen of JWH, while body temperatures and agonist-induced behaviors were measured following challenge doses of 5-HT drugs.

We hypothesized that repeated exposure to JWH would enhance subsequent behavioral responsiveness to DOI in rats [e. JWH and rimonabant were dissolved into a mix of dimethyl sulfoxide:Tween sterile saline, whereas other drugs were dissolved in sterile saline. All injections were administered at a volume of 1. After 2 weeks of acclimation to the vivarium, rats were subjected to surgical procedures and subsequently used for experiments.

Rats were rapidly anesthetized with isoflurane using a drop jar which contained a raised floor above a gauze pad saturated with 5 mL of isoflurane.

Once fully anesthetized, each rat received a surgically implanted IPTT transponder Bio Medic Data Systems, Seaford, DE, USA to facilitate the non-invasive measurement of body temperature via a portable radio frequency reader system handheld reader. Animals were individually housed postoperatively and allowed 7—10 days for recovery.

As a first step in our study, we examined the dose—response effects of acute JWH administration in a cohort of 12 rats. Rats were tested once per week for three consecutive weeks. On test day, rats were moved to the testing room in their home cages and given 1 h to acclimate. Feeding trays were removed, and wire lids were placed atop the cages. Rats received sc injections of JWH 0. Immediately before injection, and at various times thereafter 0. Observers were not blind to the drug treatment condition.

Rats were assigned a catalepsy score based on three behaviors: immobility absence of movement , flattened body posture, and splayed limbs limbs spread out away from the center of the body.

Once dose—response experiments were completed, we next tested the effect of pretreatment with the CB 1 receptor antagonist rimonabant on the responses induced by JWH in a cohort of 12 rats.

Rats were pretreated with either 1. Body temperature measurements and behavior scoring were carried out as described previously for acute dose—response experiments. Results from the acute dose—response experiments demonstrated that 1. Thus, this dose was used for the repeated injection experiments carried out in a group of 32 rats. The repeated dosing with JWH or its vehicle was carried out in the vivarium.

Rats fitted with surgically implanted sc temperature transponders received a single sc injection of either 1. Immediately before injection, and at 1, 2, and 4 h post-injection, body temperature was measured using the handheld reader, and animals were observed for 90 s.

One day after the last repeated treatment with JWH or vehicle i. One cohort of 16 rats received 0. The doses of DOI and 8-OH-DPAT were based on preliminary dose—response experiments, which identified drug doses evoking robust behavioral changes that were less than maximal data not shown.

The specific non-contingent behaviors induced by DOI were wet dog shakes and back muscle contractions i. Both behaviors are known to be mediated by 5-HT 2A receptors in rats 21 — The numbers of wet dog shakes and skin jerks present during the observation period were tallied. Wet dog shakes were defined as a rapid and sudden rotation of the head, neck, and shoulders from one side to the other, analogous to the way a wet dog may shake to dry itself.

Skin jerks were defined as brief paraspinal muscle contractions of the back muscles in a tail to head direction. Possible scores for each behavior were 0 behavior absent , 1 behavior present , or 2 behavior intense or continuous.

At the end of the observation period, the scores for the three behaviors were summed to produce a 5-HT syndrome score for each time point. After acute serotonergic drug challenge, body temperatures were measured using the handheld reader at 0. Data were tabulated, analyzed, and graphically depicted using GraphPad Prism version 5. Statistical analyses were performed on data from all 7 days of the JWH repeated administration experiment, however, Figure 3 only shows data from selected days to make the graphs easier to interpret.

The left panel of Figure 1 illustrates the effect of acute JWH administration on core body temperature in male rats. It is worth noting that 0. As seen in the right panel of Figure 1 , JWH dose-dependently increased the summed catalepsy behavioral score Kruskal—Wallis statistic Figure 1. Core temperature measures and summed catalepsy scores for rats receiving acute subcutaneous injections of 0. Core temperature and behavioral score were recorded at 0, 0. The left panel of Figure 2 shows that pretreatment with 1.

Figure 2. Core temperature measures and summed catalepsy scores for rats receiving either subcutaneous sc vehicle VEH or 1. The left panel of Figure 3 depicts the effects of 1. Because vehicle administration did not affect body temperature over the course of repeated injections, we compared the effects of JWH treatments across days to those of vehicle treatment on day 1.

On day 1 of JWH exposure, temperature was significantly reduced from vehicle at the 1, 2, and 4 h timepoints. By day 3 of treatment, hypothermia was observed only at the 1 h timepoint, and on days 6 and 7, no reduction in temperature was observed.

Figure 3. Core temperature measures and summed catalepsy scores for rats receiving either subcutaneous vehicle VEH or 1. Joshua S. Elmore 1 and Michael H. Michael H. Author information Article notes Copyright and License information Disclaimer. Baumann, vog. Specialty section: This article was submitted to Addictive Disorders, a section of the journal Frontiers in Psychiatry.

Received Aug 17; Accepted Feb 8. The use, distribution or reproduction in other forums is permitted, provided the original author s and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice.

No use, distribution or reproduction is permitted which does not comply with these terms. This article has been cited by other articles in PMC. Keywords: JWH, synthetic cannabinoid, serotonin, receptor, spice. Open in a separate window. Figure 3. Figure 1. Figure 2. Figure 4. Figure 5. Figure 6. Discussion The psychiatric literature supports a strong relationship between heavy cannabis use and risk for subsequent psychosis and schizophrenia Author Contributions JE and MB were responsible for experiment design, statistical analysis, and manuscript writing.

Conflict of Interest Statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Footnotes Funding. References 1. J Mass Spectrom 44 —7. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds.

J Mass Spectrom 45 — Springfield, VA: U. Drug Enforcement Administration; Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J Pharmacol Exp Ther — Drug Alcohol Depend — Differential drug-drug interactions of the synthetic cannabinoids JWH and JWH implications for drug abuse liability and pain therapy. Behav Pharmacol 25 —7. Cross-substitution of delta9-tetrahydrocannabinol and JWH in drug discrimination in rats. Pharmacol Biochem Behav —8.

Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull 40 — The association between cannabis abuse and subsequent schizophrenia: a Swedish national co-relative control study. Psychol Med 45 — Hamilton I. Cannabis, psychosis and schizophrenia: unravelling a complex interaction. Addiction 9 —7. Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis.

World Psychiatry 15 — Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch Gen Psychiatry 50 —8. Biol Psychiatry 55 — A proposed pathological model in the hippocampus of subjects with schizophrenia.

Clin Exp Pharmacol Physiol 28 —3. Darmani NA. Pharmacol Biochem Behav 68 —7. Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids.

Prog Neuropsychopharmacol Biol Psychiatry 39 , —, doi: Spaderna, M. Spicing thing up: Synthetic cannabinoids. Psychopharmacology , —, doi: Wiebelhaus, J. Drug and alcohol dependence , —, doi: Dhawan, J. Synapse 60 , 93—, doi: Castaneto, M. Drug and alcohol dependence 0 , 12—41, doi: Zawilska, J.

International Journal of Neuropsychopharmacology 17 , —, doi: Auwarter, V. J Mass Spectrom 44 , —, doi: Teske, J. Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalenyl- 1-pentylindolyl methanone JWH in human serum by liquid chromatography-tandem mass spectrometry.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences , —, doi: Buonamici, M.

Neuropharmacology 21 , —, doi: Karler, R. Interaction between deltatetrahydrocannabinol and kindling by electrical and chemical stimuli in mice.

Neuropharmacology 23 , — Rosenberg, E. Cannabinoids and Epilepsy. Neurotherapeutics 12 , —, doi: Lapoint, J. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol Phila 49 , —, doi: Schneir, A.

Journal of Medical Toxicology 8 , 62—64, doi: Article PubMed Google Scholar. Phytocannabinoids and epilepsy.

Journal of Clinical Pharmacy and Therapeutics 40 , —, doi: Devinsky, O. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. The Lancet Neurology 15 , —, doi: Koppel, B. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 82 , —, doi: Russo, E.

A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Medical Hypotheses 66 , —, doi: Toennes, S. Pharmacokinetic properties of the synthetic cannabinoid JWH and of its metabolites in serum after inhalation. Journal of pharmaceutical and biomedical analysis , —, doi: Hermanns-Clausen, M.

Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction , —, doi: Marshell, R. Pharmacol Biochem Behav , 40—47, doi: Sales-Carbonell, C. Striatal GABAergic and cortical glutamatergic neurons mediate contrasting effects of cannabinoids on cortical network synchrony. Smith, D. Synthetic marijuana use and development of catatonia in a year-old male. Minnesota medicine 97 , 38 Google Scholar. Khan, M. Catatonia secondary to synthetic cannabinoid use in two patients with no previous psychosis.

The American journal on addictions 25 , 25—27, doi: Wade, D. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis.